Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 2/2016

01-02-2016 | Original Paper

Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial

Authors: Julie Barroso, Angela M. Bengtson, Bradley N. Gaynes, Teena McGuinness, Evelyn B. Quinlivan, Michelle Ogle, Amy Heine, Nathan M. Thielman, Brian W. Pence

Published in: AIDS and Behavior | Issue 2/2016

Login to get access

Abstract

Fatigue and depression are common co-morbid conditions among people with HIV infection. We analyzed a population of HIV-infected adults with depression, who were enrolled in a depression treatment trial, to examine the extent to which improvements in depression over time were associated with improvements in HIV-related fatigue. Data for this analysis come from a randomized controlled trial to evaluate the effectiveness of improved depression treatment on antiretroviral adherence. Fatigue was measured using the HIV-Related Fatigue Scale, and depressive symptoms were measured with the Hamilton Depression Rating Scale. Participants (n = 234) were on average nearly 44 years of age and predominantly male, black or African American, and unemployed. Individuals who experienced stronger depression response (i.e., greater improvement in depression score) had larger decreases in fatigue. However, even among those who demonstrated a full depression response, nearly three-quarters continued to have either moderate or severe fatigue at 6 and 12 months.
Literature
1.
Erdbeer G, Sabranski M, Sonntag I, et al. Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy. J Int AIDS Soc. 2014;17(4 Suppl 3):19673.PubMedCentralPubMed
2.
Jong E, Oudhoff LA, Epskamp C, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS. 2010;24(10):1387–405.CrossRefPubMed
3.
Barroso J, Harmon JL, Madison JL, Pence BW. Intensity, chronicity, circumstances, and consequences of HIV-related fatigue: a longitudinal study. Clin Nurs Res. 2014;23(5):514–28.PubMedCentralCrossRefPubMed
4.
Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRefPubMed
5.
Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res. 2002;11(2):75–82.CrossRefPubMed
6.
Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr. 2006;42(3):298–306.CrossRefPubMed
7.
8.
Barroso J, Carlson JR, Meynell J. Physiological and psychological markers associated with HIV-related fatigue. Clin Nurs Res. 2003;12(1):49–68.CrossRefPubMed
9.
Barroso J, Hammill BG, Leserman J, Salahuddin N, Harmon JL, Pence BW. Physiological and psychosocial factors that predict HIV-related fatigue. AIDS Behav. 2010;14(6):1415–27.PubMedCentralCrossRefPubMed
10.
Barroso J, Lynn MR. Psychometric properties of the HIV-Related Fatigue Scale. J Assoc Nurses AIDS Care. 2002;13(1):66–75.CrossRefPubMed
11.
Breitbart W, McDonald MV, Rosenfeld B, Monkman ND, Passik S. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage. 1998;15(3):159–67.CrossRefPubMed
12.
Henderson M, Safa F, Easterbrook P, Hotopf M. Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med. 2005;6(5):347–52.CrossRefPubMed
13.
Millikin CP, Rourke SB, Halman MH, Power C. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol. 2003;25(2):201–15.CrossRefPubMed
14.
Paddison J, Fricchione G, Gandhi RT, Freudenreich O. Fatigue in psychiatric HIV patients: a pilot study of psychological correlates. Psychosomatics. 2009;50(5):455–60.CrossRefPubMed
15.
Schifitto G, Deng L, Yeh TM, et al. Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals. J Neurovirol. 2011;17(1):17–25.PubMedCentralCrossRefPubMed
16.
Voss JG. Predictors and Correlates of Fatigue in HIV/AIDS. J Pain Symptom Manage. 2005;29(2):173–84.CrossRefPubMed
17.
Jaggers JR, Hand GA, Dudgeon WD, et al. Aerobic and resistance training improves mood state among adults living with HIV. Int J Sports Med. 2015;36(2):175–81.PubMed
18.
Barroso J, Leserman J, Harmon JL, Hammill B, Pence BW. Fatigue in HIV-Infected people: a three-year observational study. J Pain Symptom Manage. 2015;50(1):69–79.CrossRefPubMed
19.
Phillips KD, Sowell RL, Rojas M, Tavakoli A, Fulk LJ, Hand GA. Physiological and psychological correlates of fatigue in HIV disease. Biol Res Nurs. 2004;6(1):59–74.CrossRefPubMed
20.
Association AP. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC: APA; 2013.
21.
Voss J, Portillo CJ, Holzemer WL, Dodd MJ. Symptoms cluster of fatigue and depression in HIV/AIDS. J Prev Interv Community. 2007;33:19–34.CrossRefPubMed
22.
Breitbart W, McDonald MV, Rosenfeld B, Monkman ND, Passik S. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage. 1998;15:159–67.CrossRefPubMed
23.
Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: A placebo-controlled study. J Clin Psychopharmacol. 2004;24:379–85.CrossRefPubMed
24.
Pence BW, Gaynes BN, Williams Q, et al. Assessing the effect of measurement-based care depression treatment on HIV medication adherence and health outcomes: rationale and design of the SLAM DUNC Study. Contemp Clin Trials. 2012;33(4):828–38.PubMedCentralCrossRefPubMed
25.
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737–44.CrossRefPubMed
26.
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33 quiz 34–57.PubMed
27.
Adams JL, Gaynes BN, McGuinness T, Modi R, Willig J, Pence BW. Treating depression within the HIV “medical home”: a guided algorithm for antidepressant management by HIV clinicians. AIDS Patient Care STDs. 2012;26(11):647–54.PubMedCentralCrossRefPubMed
28.
Pence BW, Barroso J, Leserman J, Harmon JL, Salahuddin N. Measuring fatigue in people living with HIV/AIDS: psychometric characteristics of the HIV-related fatigue scale. AIDS Care. 2008;20(7):829–37.CrossRefPubMed
29.
Pence BW, Barroso J, Harmon JL, Leserman J, Salahuddin N, Hammill BG. Chronicity and remission of fatigue in patients with established HIV infection. AIDS Patient Care STDs. 2009;23(4):239–44.PubMedCentralCrossRefPubMed
30.
Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278–96.CrossRefPubMed
31.
Leucht S, Fennema H, Engel R, Kaspers-Janssen M, Lepping P, Szegedi A. What does the HAMD mean? J Affect Disord. 2013;148(2–3):243–8.CrossRefPubMed
32.
Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):5–9.PubMed
33.
Carver CS. You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92–100.CrossRefPubMed
34.
Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989;56(2):267–83.CrossRefPubMed
35.
Pence BW, Thielman NM, Whetten K, Ostermann J, Kumar V, Mugavero MJ. Coping strategies and patterns of alcohol and drug use among HIV-infected patients in the United States Southeast. AIDS Patient Care STDs. 2008;22(11):869–77.PubMedCentralCrossRefPubMed
36.
Shively M, Smith T, Bormann J, Gifford A. Evaluating self-efficacy for HIV disease management skills. AIDS Behav. 2002;6(4):371–9.CrossRef
37.
McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180–6.PubMedCentralCrossRefPubMed
38.
Paykel ES. Partial remission, residual symptoms, and relapse in depression. Dialogues Clin Neurosci. 2008;10(4):431–7.PubMedCentralPubMed
39.
Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011;32(1):7–24.PubMed
40.
41.
Rabkin JG, McElhiney MC, Rabkin R. Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics. 2011;52(4):328–36.PubMedCentralCrossRefPubMed
42.
Kudel I, Cotton S, Szaflarski M, Holmes WC, Tsevat J. Spirituality and religiosity in patients with HIV: a test and expansion of a model. Ann Behav Med. 2011;41(1):92–103.CrossRefPubMed
Metadata
Title
Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial
Authors
Julie Barroso
Angela M. Bengtson
Bradley N. Gaynes
Teena McGuinness
Evelyn B. Quinlivan
Michelle Ogle
Amy Heine
Nathan M. Thielman
Brian W. Pence
Publication date
01-02-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1242-4

Other articles of this Issue 2/2016

AIDS and Behavior 2/2016 Go to the issue

Original Paper

A Comparison of Men Who Have Sex with Men, People Who Inject Drugs and High-Risk Heterosexuals’ Risk for HIV Infection, San Francisco

Original Paper

Linking Syndemic Stress and Behavioral Indicators of Main Partner HIV Transmission Risk in Gay Male Couples

Original Paper

Alexithymia, Assertiveness and Psychosocial Functioning in HIV: Implications for Medication Adherence and Disease Severity

Original Paper

High Prevalence of Assisted Injection Among Street-Involved Youth in a Canadian Setting

Original Paper

Prediction of HIV Sexual Risk Behaviors Among Disadvantaged African American Adults Using a Syndemic Conceptual Framework

Original Paper

High HIV Prevalence and Associated Risk Factors Among Female Sexual Partners of Male Injection Drug Users (MWID) in Ho Chi Minh City, Vietnam
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits